Search
-
All-cause hospitalisation among people living with HIV according to gender, mode of HIV acquisition, ethnicity, and geographical origin in Europe and North America: findings from the ART-CC cohort collaboration
(Lancet Public Health. vol. 8, n° 10, pp. 776-787, 2023-10)Article de revueOpen access -
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials
(EClinicalMedicine. vol. 65, pp. 102283, 2023-11)Article de revueOpen access -
All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019
(International Journal of Drug Policy. vol. 124, pp. 104311, 2024-01-06)Article de revue -
Estimation of Improvements in Mortality in Spectrum Among Adults With HIV Receiving Antiretroviral Therapy in High-Income Countries
(Journal of Acquired Immune Deficiency Syndromes - JAIDS. vol. 95, n° 1S, pp. e89-e96, 2024-01-01)Article de revueOpen access -
Changes in incidence of hepatitis C virus reinfection and access to direct-acting antiviral therapies in people with HIV from six countries, 2010-19: an analysis of data from a consortium of prospective cohort studies
(Lancet HIV. vol. 11, n° 2, pp. e106-e116, 2024-01-12)Article de revue -
Immunogenicity and vaccine shedding after 1 or 2 doses of rVZVDeltaG-ZEBOV-GP Ebola vaccine (ERVEBO(R)): Results from a phase 2, randomized, placebo-controlled trial in children and adults
(Clinical Infectious Diseases, 2023-11-15)Article de revueOpen access -
A vaccine targeting antigen-presenting cells through CD40 induces protective immunity against Nipah disease
(Cell Reports Medicine. vol. 5, n° 3, pp. 101467, 2024-03-19)Article de revueOpen access -
CRP under 130 mg/L rules out the diagnosis of Legionella pneumophila serogroup 1 (URINELLA Study)
(European Journal of Clinical Microbiology & Infectious Diseases, 2024-03-26)Article de revueOpen access -
Evaluating the Use of Generalized Dynamic Weighted Ordinary Least Squares for Individualized Hiv Treatment Strategies
(Annals of Applied Statistics. vol. 17, n° 3, pp. 2432-2451, 2023-09)Article de revueOpen access -
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone
(Lancet Global Health. vol. 11, n° 11, pp. e1743-e1752, 2023-11)Article de revueOpen access